文献速递头颈部肿瘤放疗泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗

循证放疗的人群获益:5年局部控制与总生存获益

The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits.
PubMed 文献 · Radiother Oncol · 2017-12-08

该研究利用澳大利亚决策树模型,评估在高收入地区常规遵循循证指南时放疗的人群获益。结果显示48%的癌症患者有放疗指征,单纯放疗为全部癌症患者提供10.4%的5年局部控制获益和2.4%的5年总生存获益,同步放化疗额外提供0.6%的局部控制和0.3%的总生存获益。

要点

  • 48%的癌症患者有放疗指征,其中34%为根治性,14%为姑息性。
  • 单纯放疗为全部癌症患者提供10.4%的5年局部控制获益和2.4%的5年总生存获益。
  • 同步放化疗额外提供0.6%的5年局部控制和0.3%的5年总生存获益。

核心结论

  • 放疗作为循证癌症治疗的一部分,提供显著的5年局部控制和总生存获益。
  • 同步放化疗提供适度的额外获益。

研究设计与样本

  • 采用澳大利亚决策树模型,系统检索文献数据库获取获益数据,并进行荟萃分析和敏感性分析。

主要发现

  • 48%的癌症患者有放疗指征,34%为根治性,14%为姑息性。
  • 单纯放疗为全部癌症患者提供10.4%的5年局部控制获益(95%CI 9.3, 11.8)和2.4%的5年总生存获益(95%CI 2.1, 2.7)。
  • 同步放化疗额外为全部癌症患者提供0.6%的5年局部控制获益(95%CI 0.5, 0.6)和0.3%的5年总生存获益(95%CI 0.2, 0.4)。
  • 单纯放疗获益最大者为头颈部肿瘤(局部控制32%,总生存16%)和宫颈癌(局部控制33%,总生存18%)。
  • 同步放化疗局部控制获益最大者为直肠癌(6%),总生存获益最大者为宫颈癌(3%)和脑肿瘤(3%)。

临床怎么用

  • 应常规遵循循证指南,以最大化放疗的人群获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To describe the population benefit of radiotherapy in a high-income setting if evidence-based guidelines were routinely followed. METHODS: Australian decision tree models were utilized. Radiotherapy alone (RT) benefit was defined as the absolute proportional benefit of radiotherapy compared with no treatment for radical indications, and of radiotherapy over surgery alone for adjuvant indications. Chemoradiotherapy (CRT) benefit was the absolute incremental benefit of concurrent chemoradiotherapy over RT. Five-year local control (LC) and overall survival (OS) benefits were measured. Citation databases were systematically queried for benefit data. Meta-analysis and sensitivity analysis were performed. FINDINGS: 48% of all cancer patients have indications for radiotherapy, 34% curative and 14% palliative. RT provides 5-year LC benefit in 10.4% of all cancer patients (95% Confidence Interval 9.3, 11.8) and 5-year OS benefit in 2.4% (2.1, 2.7). CRT provides 5-year LC benefit in an additional 0.6% of all cancer patients (0.5, 0.6), and 5-year OS benefit for an additional 0.3% (0.2, 0.4). RT benefit was greatest for head and neck (LC 32%, OS 16%), and cervix (LC 33%, OS 18%). CRT LC benefit was greatest for rectum (6%) and OS for cervix (3%) and brain (3%). Sensitivity analysis confirmed a robust model. INTERPRETATION: Radiotherapy provides significant 5-year LC and OS benefits as part of evidence-based cancer care. CRT provides modest additional benefits.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna TP, Shafiq J, Delaney GP, et al. The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits. Radiother Oncol. 2017. PMID: 29229506. doi:10.1016/j.radonc.2017.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。